Jeffrey Leiden, M.D., Ph.D. is an award-winning physician-scientist, entrepreneur, advisor and academic, who serves as Executive Chairman at Vertex Pharmaceuticals.
He spent eight years as Chairman, President and CEO of Vertex and helped pioneer the first medicines in history to treat the underlying cause of cystic fibrosis. Dr. Leiden has been involved with Vertex for over a decade, having first served as a board member. His leadership has been defined by innovation and a commitment to developing transformative medicines. He is passionate about giving back to the community and making STEM education accessible to underrepresented students and has initiated many programs through Vertex and public-private partnerships to support this.
Prior to Vertex, Dr. Leiden was a Managing Director of Clarus Ventures, a venture capital firm focused on life sciences investments. He also served as President, COO and CSO at Abbott Laboratories, where he oversaw the company’s pharmaceutical business globally. Consistently committed to achieving life-changing strides in medicine, Dr. Leiden led the development of numerous medicines at Abbott.
Earlier in his career, Dr. Leiden was appointed as Professor of Medicine at Harvard Medical School and Elkin R. Blout Professor of Biological Sciences at the Harvard School of Public Health. In addition to his academic appointments, he worked as a physician, having been appointed as Chief of Cardiology at The University of Chicago Medical Center, where he was also the Rawson Professor of Medicine and Pathology and an Attending Physician. During this time, he co-founded several biotechnology companies including Vical and Cardiogene.
Dr. Leiden has held many board positions throughout his career and currently serves as Chairman at Casana, a health monitoring platform, as well as Tmunity Therapeutics, a biotherapeutics company.
Dr. Leiden has been presented with numerous awards, including the Forbes Lifetime Achievement Award.